Cargando…
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
BACKGROUND: The proteasome inhibitor bortezomib (BTZ) is successfully applied in the treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of resistance. Metabolic alterations play an important role in cancer development and aid in the cellular adaptation to pha...
Autores principales: | Zaal, Esther A., Wu, Wei, Jansen, Gerrit, Zweegman, Sonja, Cloos, Jacqueline, Berkers, Celia R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575874/ https://www.ncbi.nlm.nih.gov/pubmed/28855983 http://dx.doi.org/10.1186/s40170-017-0169-9 |
Ejemplares similares
-
Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation
por: Chen, Jing, et al.
Publicado: (2021) -
Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment
por: Matamala Montoya, María, et al.
Publicado: (2023) -
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021) -
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
por: Niewerth, Denise, et al.
Publicado: (2014) -
Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis
por: de Groot, Karina A, et al.
Publicado: (2015)